# Tools4Patient

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tools4patient-s-a

- Industry: Healthcare IT
- Headquarters: Charleroi, Belgium
- Website: www.tools4patient.com
- Total disclosed funding: $3.2M
- Latest round: Series B (May 3, 2019)
- Investors on record: 2

## About

Tools4Patient, S.A. provides innovative solutions aimed at streamlining clinical trials and enhancing drug efficacy outcomes through advanced data modeling and analytical tools.Founded in 2013 and headquartered in Charleroi, Belgium, Tools4Patient, S.A. specializes in clinical trial technologies. The company received EUR 4 million in Series B funding in May 2019 from Innovation Fund and Sambrinvest, facilitating its operational expansion. Dominique Demolle leads the company as CEO, steering it towards improved patient engagement strategies.Tools4Patient, S.A. develops advanced solutions for clinical trials, focusing on reducing data variability and predicting patient behaviors. Their core products, Placebell™ and Compl-AI™, help pharmaceutical and biotech companies gain insights into treatment efficacy and patient adherence during clinical trials.In 2023, Tools4Patient, S.A. reported an EBITDA of EUR 205,127.90. The company's revenue model is based on partnerships and subscriptions with pharmaceutical and biotech clients, allowing for the integration of their technologies into clinical trial processes to enhance patient engagement and data analysis.Following its Series B funding in May 2019, Tools4Patient, S.A. plans to leverage the EUR 4 million raised to enhance its product offerings and expand into new markets. The company is focused on developing additional features for Placebell™ and Compl-AI™, aiming for release in the coming years, while targeting growth in North America and parts of Asia by 2025.

## Funding rounds

- Series B, May 3, 2019, $3.2M — Sambrinvest, Innovation Fund

## Investors

- Sambrinvest (https://capitalatlas.ai/funds/sambrinvest) — Series B
- Innovation Fund (https://capitalatlas.ai/funds/innovation-fund) — Series B